Here are the S-1 registration statements from Interpace Biosciences New (IDXG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow IDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXG filings page.
Interpace Biosciences, Inc. is offering 3,100,000 shares of common stock in a firm-commitment underwritten offering, with a preliminary public price range of $6.00 to $7.00 per share.
At the assumed $6.50 price, Interpace estimates net proceeds of approximately $17.9 million, or approximately $20.8 million if the underwriters exercise their option for up to 465,000 additional shares in full. The offering’s closing is contingent on conditional Nasdaq listing approval; Interpace says it will not consummate the offering if its listing application is not approved. Proceeds are intended for working capital, capital expenditures and general corporate purposes, with possible use for test development or complementary investments. At $6.50, the company estimates immediate dilution of $2.03 per share to new investors.
Interpace sells molecular diagnostic tests focused on thyroid cancer after Medicare reimbursement ended for its PancraGEN pancreatic test and it stopped accepting specimens for that test. Thyroid-only pro forma revenue was $34.8 million in 2025 versus $20.3 million in 2022; adjusted EBITDA was $4.4 million versus a $4.9 million loss. A new pancreatic cyst test is in development, with analytical validation underway and clinical validation and utility studies planned across 2026 and 2027.
Interpace Biosciences, Inc. (IDXG) proposes a firm-commitment underwritten offering of 3,100,000 shares of common stock. The estimated price range is $6.00 to $7.00 per share, with final pricing to be set with the underwriter. A 30-day option permits the underwriter to buy up to 465,000 additional shares to cover over-allotments.
At an assumed $6.50 per share, Interpace estimates net proceeds of approximately $17.9 million, or $20.8 million if the option is fully exercised. It plans to use proceeds for working capital, capital expenditures and general corporate purposes; some may support development of pancreatic cyst and Barrett’s Esophagus tests or investments in complementary businesses, technologies, products or assets. Closing is contingent on conditional Nasdaq listing approval; if the application is not approved, Interpace will not complete the offering.
Interpace focuses on its ThyGeNEXT and ThyraMIRv2 thyroid tests after discontinuing PancraGEN following loss of Medicare reimbursement. Its thyroid-only pro forma results report 2025 revenue of $34.8 million and adjusted EBITDA of $4.4 million, excluding PancraGEN revenue and related costs. At the assumed price, the company estimates immediate net tangible book value dilution of $2.03 per share for purchasers.
Interpace Biosciences, Inc. (IDXG) is offering $20,000,000 of common stock in a firm commitment underwritten offering. It estimates net proceeds of approximately $17.8 million, or approximately $20.6 million if the underwriter exercises its 30-day option to purchase up to an additional $3,000,000 of common stock solely to cover over-allotments.
The company intends to use proceeds for working capital, capital expenditures and general corporate purposes; it may also use a portion for developing pancreatic cyst and Barrett’s Esophagus tests or investing in complementary businesses, technologies, products or assets. Closing is contingent on conditional Nasdaq listing approval; if its application is not approved, the company says it will not consummate the offering. The public offering price will be set at pricing. The $6.47 last reported OTCID sale price on September 22, 2026, is used as the assumed price in the company’s estimate of $2.01 per-share dilution to purchasers. A 1-for-5 reverse split took effect August 27, 2026. Thyroid-only pro forma revenue, excluding PancraGEN, was $34.8 million in 2025; the company reports a 19.7% CAGR from 2022 through 2025.